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Abstract
Metformin is currently considered a first-line therapy in type 2 diabetic patients. After issuing warnings for decades about 
the risks of lactic acidosis in patients with chronic nephropathy, metformin is now being re-evaluated. The most recent 
evidence from the literature has demonstrated both a low, acceptable risk of lactic acidosis and a series of favorable effects, 
which go beyond its hypoglycemic activity. Patients treated with metformin show a significant mortality reduction and lower 
progression towards end-stage renal disease in comparison with those treated with other hypoglycemic drugs. Concerning 
lactic acidosis, in the last few years it has been shown how lactic acidosis almost always developed when patients kept tak-
ing the drug in the face of a concomitant disease or situation such as sepsis, fever, diarrhea, vomiting, which reduced met-
formin renal clearance. Actually, clearance of metformin is mainly renal, both by glomerular filtration and tubular secretion 
(apparent clearance 933–1317 ml/min, half-life < 3 h). As regards treatment, in cases of lactic acidosis complicated by acute 
kidney injury, continuous renal replacement therapy (CRRT) plays a crucial role. Besides the elimination of metformin, 
CRRT  improves survival  by correcting acidosis, electrolyte alterations, and maintaining fluid balance. Lactic acidosis 
almost always develops because of preventable drug accumulation. Therefore, prevention is a key factor. Patients should be 
aware that discontinuation for a limited time does not affect their health, even when it may be inappropriate, but it may avoid 
a serious, potentially fatal adverse event.
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Introduction
In April 2016, the Food and Drug Administration (FDA) 
stated that the antidiabetic drug metformin could be used “in 
patients with mild renal failure and, in particular situations, 
even moderate” [1].
After issuing warnings for decades about the risks of 
metformin-induced lactic acidosis in patients with chronic 
kidney disease (CKD), the FDA concluded that the previous 
guidelines were overly restrictive for metformin. Metformin 
was approved in 1995, with contraindication in patients 
with renal disease or dysfunction (serum creatinine lev-
els > = 1.5 mg/dl for males and > = 1.4 mg/dl for females), 
or in the presence of impaired creatinine clearance.
Although lactic acidosis, the main complication related to 
the use of metformin, was a serious and potentially fatal con-
dition, during the last 20 years a higher rate of lactic acidosis 
has not been found in patients taking metformin compared 
to the general population [2–4]. Furthermore, some inves-
tigations have shown that in the real world metformin was 
used in high percentages in patients below the kidney func-
tion threshold values set by the FDA ((creatinine of 1.5 mg/
dl for males, and 1.4 mg/dl for females)). Nonetheless, no 
significant increase in lactic acidosis cases occurred, and 
when cases did occur in metformin-treated patients, they 
were almost always associated with some triggering event 
such as sepsis, or severe hemodynamic failure. Therefore, 
for CKD diabetic patients suffering from a syndrome rather 
than a single disease, metformin was simply a risk factor 
that predisposed to the onset of a severe complication [5–7].
After 2016 the European Medicines Agency (EMA) 
started reviewing the use of metformin in patients with dif-
ferent levels of renal impairment, aiming at harmonizing the 
prescription in all European Union countries. After years 
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of consolidated use, metformin has proved to be a safe and 
efficient drug, with a favorable cost-benefit ratio (as high as 
not to be comparable) to any other antidiabetic drug.
On the horizon of diabetes therapy, new “players”, such 
as sodium-glucose co-transporter type 2 inhibitors (SGLT2i) 
and glucagon-like peptide 1 receptor agonists (GLP1RA) 
are currently emerging. Even though their real role in the 
future of diabetic therapy is not fully defined, SGLT2i and 
GLP1RA have great potential for the prevention of cardio-
vascular (CV) risk and CKD in diabetic patients [8, 9]. The 
recent guidelines of the ESC 2019 and the ADA-EASD 2020 
Consensus suggested adding these drugs to metformin to 
reach the HbA1c target, and in high-risk CV patients regard-
less of the HbA1c values achieved with metformin treatment 
[8–12].
The intrinsic value of the metformin molecule remains 
undisputed for patients with CKD as it is always the first-
line drug treatment, at least as long as estimated glomerular 
filtration rate (eGFR) is ≥ 30 ml/min/1.73 m2 [11, 12], even 
though some concerns remain regarding the reported asso-
ciation with lactic acidosis.
The purpose of this paper is to provide a nephrologist’s 
point of view on the relationship between metformin, renal 
function, CKD, and its potential long-term benefit. We will 
also focus on lactic acidosis requiring renal replacement 
therapy (RRT), with an update on the modalities of dialysis 
that are more appropriate for this severe complication.
Metformin and renal function
Metformin (dimethylbiguanide, MW 129.17 daltons) was 
first synthesized in 1922, and since 1958 it has been used in 
the control of hyperglycemia in type II diabetes [13]. Met-
formin is a biguanide, chemically developed from galegina, 
a natural guanidine compound found in Galega Officinalis 
(French lilac).
Metformin is the natural successor of phenformin, that 
was used as the reference oral biguanide for many years. 
Phenformin is a hydrophobic molecule, rapidly absorbed 
by the intestine, extensively metabolized in the liver to 
4-hydroxy-phenformin, and with a long half-life of 11 h 
[14]. Phenformin was withdrawn from the market in the late 
1990 s for inducing fatal lactic acidosis, mainly related to the 
different ability of the subjects to metabolize the drug in the 
liver. In subjects with low metabolic capacity, accumulation 
of the drug and toxic levels occurred leading to potential 
fatal lactic acidosis [15, 16]. As shown in Fig. 1, metformin 
has 2 methyl groups instead of a phenyl group of phenformin 
[17]. At physiological pH, metformin is a cationic hydro-
philic molecule (> 99.8%). Despite its low molecular weight, 
its chemical characteristics strongly limit passive diffusion 
in cell membranes. Furthermore, unlike phenformin, met-
formin does not undergo metabolism and it is eliminated 
unchanged [13].
Erythrocytes can slowly uptake metformin. Six hours 
after a single dose, when plasma concentrations are negligi-
ble, metformin concentrations in erythrocytes exceed those 
in plasma. Erythrocytes work like a separate compartment, 
which slowly keeps releasing the accumulated drug. How-
ever, this prolonged elimination by the erythrocyte compart-
ment challenges the traditional view that the drug could be 
shortly cleared even after short dialysis therapy. In the case 
of lactic acidosis due to accumulation of metformin, the drug 
is detected in plasma and erythrocytes for up to 13 days [18].
Metformin is administered per os 2–3 times a day in a 
cumulative dose that rarely exceeds 3 g/day. Metformin is 
absorbed in the upper part of the small intestine (duode-
num, jejunum) through specific membrane transporters. 
Gastrointestinal absorption is incomplete, with a discrete 
intra-subject as well as inter-subject variability. The mean 
bioavailability (F) is at about 55% [13, 19].
Metformin plasma protein binding is negligible. In 
healthy and/or diabetic patients with normal renal function 
metformin half-life is 3–5 h depending on the oral formula-
tion (immediate or extended-release) (see Table 1).
The elimination of the drug takes place in the urine, by 
tubular secretion, and as an unchanged drug. After oral 
administration, the mean renal clearance and apparent total 
clearance (Clear/F) are estimated to be 510 ± 130 ml/min 
and 1140 ± 330 ml/min, respectively. These values, which 
are 4.3 and 10.7 times the creatinine clearance, underline 
the role of the kidney in metformin elimination. Since met-
formin clearance always maintains a direct proportion to 
creatinine clearance for the different values of renal function 
Fig. 1  Chemical structure of 
biguanides metformin and 
phenformin
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[20], with an increasing degree of renal failure the dosage 
should be proportionally decreased (Table 1).
Intestinal absorption, liver uptake, and renal excretion are 
largely mediated by the specific transport system Organic 
Cation Transporter (OCTs) and Multidrug And Toxin Extru-
sion Transporter (MATE) [19]. Specific variants of these 
transporters (OCT1, polymorphism rs622342) are known to 
have been associated with a decreased hypoglycemic effect 
in heterozygotes, and with a missing effect in homozygotes. 
The specific transporter variants can significantly change 
absorption, hepatic uptake, and renal secretion, and therefore 
they can modulate the pharmacokinetics/pharmacodynamics 
of metformin in the individual subject [21].
Metformin prescription
Current guidelines state that in normal subjects 
(eGFR > 90 ml/min) the usual starting dose varies between 
500 mg and 850 mg of metformin 2 or 3 times a day during 
or after meals, with a maximum recommended daily dose of 
3 g. In patients with renal impairment, eGFR must be evalu-
ated before starting treatment, and subsequently at least once 
a year, or at least every 3–6 months for patients with eGFR 
30–59 ml/min (11,12). Regarding the dose, in patients with 
eGFR between 60 and 89 (stage II KDIGO) the maximum 
dose should be less than 3 gr/day in 2–3 administrations, 
in patients with eGFR between 45 and 59 ml/min the dose 
must be less than 2 gr/day, and between 30 and 44 ml/min 
less than 1 gr/day.
Metformin is contraindicated in patients with eGFR 
less than 30 mL/min [11, 12, 22]. In patients with eGFR 
between 30 and 60 mL/min, the known factors increasing 
the risk of lactic acidosis (other drugs, serious respiratory 
and circulatory comorbidities, septic state, liver failure) 
must be examined before considering the start of met-
formin treatment. Furthermore, the starting dose should 
not exceed half the maximum indicated dose [11, 12, 22].
Table 1  Pharmacology of 
metformin in normal subjects 
and in chronic renal failure 
(adapted from 13,18–20)
a Values are referred to patients with type 2 diabetes mellitus with normal renal function
b The values are referred for oral IR formulations and to the different stage of renal failure for chronic renal 
failure (Ref [19, 20])
c Plasma peak levels for XR formulation and as equal split doses for IR formulation
d Recommended daily doses for XR formulation and as equal split doses for IR formulation. Doses in 
chronic renal failure are according to renal function (Ref 20)
Clear/F clearance after oral administered dose, BCrC blood creatinine clearance, IR immediate release, XR 
extended release
Parameter Normal subjects Chronic renal failure
Bioavailability (%) 50–60 50–60
Distribution volume (L)a 500–600 –
Half-life (hours)b 3.0 4.5–13.0
Clear/F (ml/min)b 933–1317 200–850
Toxic threshold plasma level (mg/L)c 5.0 5.0
Threshold-dose (p.o mg/day)d BCrC 120 ml/min 3000 –
 BCrC 60 ml/min – 2000
 BCrC 30 ml/min – 1000
 BCrC 15 ml/min – 500
Table 2  Demographic data and RRT parameters of 117 metformin-
associated lactic acidosis patients admitted in ICUs and treated with 
renal replacement therapy (modified from Ref. [45])
RRT renal replacement therapy, HF hemofiltration, HDF hemodia-
filtration, CRRT continuous renal replacement therapy, PIRRT pro-
longed intermittent renal replacement therapy
Patients no. (F/M) 76/41 (64.9%)
ICU survival (survived/dead, %) 92/25 (78.6%)
Age (years, mean) 71.6
At RRT start
Creatinine (umol/L, mean) 598.8
pH (arterial blood, mean) 7.04
Lactate (mmol/L, mean) 12
Time interval before RRT start (hours, mean) 3.2
RRT clinical parameters
Duration of RRT (days, mean) 3.9
Dialysis dose (ml/Kg/day, mean) 977.7
Predilution (% of infusion, mean) 31.8
Heparin anticoagulant 84/19 (81.5%)
HF or HDF techniques (yes/no (%)) 91/18 (83.4%)
CRRT or PIRRT modalities (yes/no (%)) 87/22 (79.8%)
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Metformin and CKD
The use of metformin in CKD has always been controversial 
and strongly limited in the last decades by the potential cases 
of associated lactic acidosis [6, 11, 12, 23].
However, for patients with CKD recent evidence has 
demonstrated on one hand a low risk of lactic acidosis [23], 
and on the other a series of favorable effects that go beyond 
hypoglycemic activity, including the possibility of slowing 
down the decline of renal function [3, 4, 24–28].
In 2010, for the first time, a metformin protective effect for 
patients with chronic renal failure was described in a cohort 
of 19,691 patients with type II diabetes and documented ath-
erosclerotic disease. In the subgroup of 5031 patients with 
KDIGO stage III nephropathy (eGFR 30–60 ml/min) mortal-
ity rate was significantly lower in metformin-treated patients 
than in non-metformin-treated patients. This effect was more 
evident in patients with chronic KDIGO stage III-B (eGFR 
30-45 ml/min) [3].
In 2012, a second large study confirmed the positive rela-
tionship between metformin and mortality in CKD patients. 
A national study, carried out in Sweden on 51,675 diabetic 
patients, showed that in patients with CKD KDIGO stage 
III-A (eGFR 45-60 ml/min) the use of metformin in mono-
therapy for a median follow-up of 3.9 years was associated 
with significant cardiovascular protection and reduced mor-
tality without any significant increase in lactic acidosis rate 
[4]. In 2017, a meta-analysis of 5 large studies on metformin 
use among adults with type 2 diabetes and comorbid mod-
erate-to-severe CKD (eGFR < 45 mL/min/1.73m2 or even 
30 mL/min), chronic heart failure, or chronic liver disease 
with impaired hepatic function demonstrated that the relative 
chance of dying during follow-up was 22% lower for patients 
taking metformin than for those not taking it (HR 0.78; 95% 
CI 0.63–0.96) [25].
Other reports focusing on patients with CKD confirmed a 
significant reduction in major cardiovascular events (MACE) 
in metformin-treated subjects compared to sulphonylurea-
treated ones [26–28]. As to the severity of impaired renal 
function, metformin should not be used in patients with 
eGFR < 30 ml/min (stage 5 KDIGO) because of an observed 
significant increased mortality. Conversely, metformin was 
safe when used in patients with eGFR > 30 ml/min/1.73 
m2 [29, 30]. As to the risk of acidosis, in a large cohort of 
patients with eGFR of at least 30 mL/min/1.73 m2, met-
formin was not associated with incident hospitalization with 
acidosis, even after accounting for a change in eGFR stage 
over time. In comparison with metformin nonuse, there was 
a higher acidosis risk associated with use only at eGFR 
less than 30 mL/min/1.73 m2 (adjusted HR, 2.07; 95% CI, 
1.33–3.22) [31].
Interestingly, after the FDA changed the labeling 
regarding metformin contraindications for diabetes 
patients with CKD, by eGFR and not by creatinine val-
ues, a reduction in racial and sex disparities of metformin 
prescription was observed. Before 2016, Black patients 
with eGFR of 30–44 ml/min/1.73 m2 were prescribed met-
formin less often than their White counterparts, whereas 
this phenomenon was significantly attenuated after the 
FDA label change (aPR, 0.90; 95% CI, 0.74–1.09; P value 
for interaction by period = 0.04) [32].
A recent retrospective, observational paper studied the 
primary outcomes (mortality and progression of chronic 
kidney disease) and the secondary outcome (incidence of 
lactic acidosis) of 10,862 type 2 diabetic patients with 
CKD for a long average follow-up of 7.3 ± 4.8  years. 
Mortality was significantly reduced for 4597 “metformin-
users” compared to 6265 “no metformin-users”. In addi-
tion, the study demonstrated significantly reduced pro-
gression towards end-stage renal disease (ESRD) assessed 
as renal replacement treatment need (aHR 0.66; 95% 
CI 0.59–0.76; P = 0.001) [33]. The significantly slower 
decline of renal function in “metformin-users” vs “no-
metformin users” was also present after data analysis with 
“Propensity Score Matching”, and with Kaplan–Meier 
curves constructed with patient stratification according 
to KDIGO stage 3 and stage 4. In particular, the benefit 
on mortality and progression of nephropathy was most 
evident for patients with eGFR between 30 and 44 ml/min 
[33]. As regards safety, only one case of lactic acidosis 
associated with metformin use was demonstrated (aHR 
0.92; 95% CI 0.668–1.276; P = 0.629) [33].
The metformin protective effects described above were 
not seen in the TREAT study, which failed to demonstrate 
the statistical significance of a renal protective effect (aHR 
1.01; 95% CI 0.65–1.55; P = 0.98) [30]. It has been hypothe-
sized that this result discrepancy was due to the short follow-
up of the TREAT study (average follow-up: 2.5 years, with 
a maximum of 4.5 years) [30]. To highlight a significant 
risk reduction on the progression towards ESRD, metformin 
treatment is required for more than 2.6 years, and more than 
4.5 years when considering 95% CI [33].
Several experimental data support the observed met-
formin-induced renal protection. Metformin exerts its meta-
bolic cellular effects essentially through an activated AMP-
protein kinase (AMPK) pathway [34]. The AMPK pathway 
is important not only for increased peripheral glucose uptake 
and (in the path of) gluconeogenesis (both related to insulin 
signal), but also for the mechanisms of cell stress protection. 
In tubular cells either a hyperglycemic state or proteinuria 
down-regulates defensive mechanisms, such as the AMPK 
pathway and autophagocytosis, and up-regulates pathologi-
cal pathways such as those of epithelial-to-mesenchymal 
transition, oxidative stress, hypoxia, and apoptosis [35]. 
Metformin has the intrinsic potential of reducing tubulo-
interstitial fibrosis, the epithelial-mesenchymal transition, 
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and the expression of TGF-1beta, a well-known fibrogenic 
factor [35, 36].
Metformin, lactic acidosis and AKI
Metformin-associated lactic acidosis (MALA) is defined by 
a blood lactate level ≥ 5 mmol/L, decreased pH and bicar-
bonates, and an increased anion gap. The therapeutic range 
of metformin is 2–4 mg/L. In MALA patients, metformin 
blood levels are generally high, largely exceeding 5 mg/L, 
and the therapeutic range of 2-4 mg/L [37, 38]. Metformin 
at a high dose exerts per se toxic effects. In healthy patients 
during (anti-preservative attempts) with metformin at high 
doses, the high blood concentrations of metformin exceeding 
50 mg/L induced a state of severe lactic acidosis (lactate lev-
els > 25 mmol/L) burdened by a high mortality rate [37, 38].
The lactate increase means an increased lactate/pyru-
vate ratio. Generally speaking, the mechanisms underlying 
lactate increase and biguanide intoxication involve several 
metabolic pathways [34]. Metformin can inhibit the mito-
chondrial respiratory chain (complex 1) and mitochondrial 
glycerophosphate dehydrogenase, and therefore direct the 
cell towards an anaerobic respiratory shift [34, 39]. Accu-
mulated pyruvate upstream from Krebs cycle is converted to 
lactate by lactic dehydrogenase. Furthermore, lactate cannot 
be efficiently consumed in liver gluconeogenesis because of 
inhibition of the pathway by metformin in an oxide-reduc-
tion-dependent manner [39]. Therefore, lactate increase is 
sustained both by excess production and reduced consump-
tion in the liver.
However, in clinical settings the real role of metformin 
in MALA onset is still not well defined. As a matter of fact, 
it has been shown that the incidence of lactic acidosis for 
metformin users was not substantially different from that 
observed in patients treated with other oral hypoglycemic 
agents [23], and risk factors such as the presence of renal 
failure, cardiovascular disease and age > 65 years, were 
crucial for the onset of lactic acidosis [23]. Furthermore, 
even if metformin did not increase the risk of acute kidney 
injury (AKI) [40], AKI is still a clinical condition that is fre-
quently described in association with MALA [41–45], and 
the decline of renal function paralleled the accumulation of 
metfomin at plasma levels capable of inducing lactic acido-
sis [41, 42]. In addition, in AKI patients MALA is worsened 
as the kidney fails the function of a lactate-consuming organ.
Metformin, lactic acidosis and RRT 
Data concerning the incidence of severe MALA cases 
requiring RRT are scarce, often incomplete, and not so 
conclusive. A recent survey in north-west Italy focused on 
MALA cases admitted to the ICU and needing renal replace-
ment therapy for AKI [45]. The source of data was the 
network of Nephrology and Dialysis Centers of Piedmont-
Aosta Valley regions, where all ICU replacement treatments 
involved the nephrology community [46].
In 2012, 17 patients suffering from a serious form of 
MALA were admitted to the ICU of Piedmont-Aosta Valley 
regions requiring renal replacement therapy (MALA-RRT 
patients) (Fig. 2). According to the Diabetes Registry [47], 
Fig. 2  Flow chart of RRT-
MALA cases recorded in 
Piedmont and Aosta Valley 
regions in 2012 (modified from 
Ref 45). RRT-MALA: cases 
of metformin-associated lactic 
acidosis treated with renal 
replacement therapy
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289,970 inhabitants (5.46%) out of 5,298,000 were affected 
by diabetes, and 231,024 (4.36% of the population) were 
treated with drugs. Of these 231,024 diabetics, 141,174 
patients (61.1%) were on metformin therapy. Therefore, in 
2012 the incidence of MALA-RRT patients in north-west 
Italy was 12.04 cases/100,000 metformin-treated patients 
(Fig. 2).
Over a 6-year period from 2010 to 2015, 117 cases 
of MALA-RRT occurred, with a survival rate of 78.3% 
(92/117) (Table 2). At admission, all MALA-RRT patients 
had a picture of AKI stage III, and in 35% of cases AKI was 
superimposed on CKD. Most of the patients (> 70%) were 
shocked and required cardio-circulatory support with vaso-
active amines, and septic shock was diagnosed in 25% of 
patients. Oliguria or anuria was present in 90% of patients, 
and dehydrationand/or gastrointestinal losses were observed 
in 80% of patients. Surprisingly, the metformin mean dose 
prescribed in MALA-RRT patients was relatively low (1.6 g/
day) [45]. Gastrointestinal losses and dehydration status 
likely played an important role in the accumulation of met-
formin driven by impaired renal clearance.
In 2020, a French observational study [48] involving 133 
patients reported similar data. Sepsis was reported in 77/133 
patients (58%), a shock condition in 64/133 patients (48%), 
and digestive disorders in 87/133 patients [48].
Current evidences for extracorporeal treatment 
of MALA‑RRT patients
Current guidelines for the use of RRT in MALA patients 
state that RRT is recommended in case of lactic acid con-
centration > 20 mmol/L, pH ≤ 7.0, shock, failure of standard 
supportive measures, or decreased level of consciousness 
[49].
Metformin is a small hydrophilic molecule (MW 165 D) 
with negligible protein binding (< 1.1%). The diffusive tech-
nique at high blood flow allows high metformin clearance 
from plasma up to 170 ml/min, and due to its high clearance 
rate hemodialysis was considered the first-line therapy for 
MALA patients [49].
However, over the years convective or mixed techniques 
in continuous or prolonged modalities have shown a high 
survival rate of MALA patients, despite being applied at a 
fluid exchange rate much lower than classical hemodialy-
sis (41,45,48,50,51). Keller et al (50) treated 6 patients (3 
continuous venovenous hemodiafiltration [CVVH], 3 con-
tinuous venovenous hemodialysis [CVVHD]) by continuous 
renal replacement therapy (CRRT) with a favorable outcome 
in all cases. They demonstrated a significant improvement 
in metabolic acidosis and reduction of plasma metformin 
concentrations within the first 24 h, and normalization on the 
second day. CRRT was carried out early, at a mean effluent 
flow rate of 34 ± 6 ml/kg/h. A protective effect of RRT was 
suggested by Peters et al. [41] who found that the 30% mor-
tality rate was similar for 16 patients treated with intermit-
tent hemodialysis and for 14 non-dialyzed subjects, despite 
greater illness severity in the former group.
Most cases of MALA admitted to ICUs are subjects with 
typical chronic metformin toxicity associated with volume 
depletion, and/or AKI with oligo-anuria. Taking into account 
the high volume of distribution of metformin (up to 600 L) 
and the time-dependent partitioning of metformin over time 
into the intracellular compartment, extracellular compart-
ment, red blood cells, and plasma, metformin becomes less 
and less available for removal when hemodialysis at high 
blood flow rate (QB) is used. In a recent report on MALA 
related to massive ingestion of metformin (plasma met-
formin peak concentration of 40.7 ug/L) and AKI treated 
by hemodialysis for 6 h, the mean whole blood and plasma 
clearances of metformin were 37.74 and 47.27 mL/min (QB 
250 ml/min, dialysate flow rate [QD] 600 ml/min, high-flux 
polysulfone filter 1.8 m2, metformin sieving coefficient of 
0.15) [52]. During hemodialysis urine output recovered, and 
mean urine clearance was 21.88 mL/min. The amount of 
removed metformin was 888 mg by 6 h of hemodialysis, 
and 142 mg in the urine during this time [52]. Thus, 6 h of 
hemodialysis was poorly efficient as it removed only a « tab-
let » of metformin.
Conversely, the amount of metformin removed by con-
tinuous treatment can be more efficient. Continuous treat-
ment works at a lower effluent rate of 40–50 ml/min, but for 
a long enough time to allow the drug to balance between the 
body compartments. Furthermore, clinical experience shows 
that when the CRRT improves hemodynamic instability and 
acid–base status, lactate concentration usually decreases and 
urine output recovers. Therefore, besides the elimination of 
metformin CRRT plays a crucial supportive role for the ini-
tial survival of the patients by correcting acidosis, electrolyte 
alterations, and maintaining fluid balance.
In the experience of 117 RRT-MALA patients treated 
in ICUs, at the start of RRT mean plasma creatinine value 
was 598 umol/L, and mean pH and lactate levels were 7.04 
and 12 mmol/L, respectively. RRT started early, at a mean 
of 3.2 h after admission, and lasted a mean of 3.9 days 
(Table 2). The mortality rate was 21.4%. Continuous or 
prolonged modalities or RRT, as well as pure convective or 
mixed treatments, were applied in more than 80% of patients 
at a mean dialysis dose of 977 ml/Kg/day (Table 2).
Even if the best modality of RRT for MALA patients 
is not clearly defined [49], it is conceivable that the ideal 
extracorporeal treatment should be early and continuous (or 
at least prolonged), and should last until a sustained cor-
rection of acid–base status and hemodynamic stability are 
obtained (Table 3). Current guidelines suggest that cessation 
of extracorporeal treatment is indicated when lactate con-
centration is less than 3 mmol/L and pH is more than 7.35 
1133Journal of Nephrology (2021) 34:1127–1135 
1 3
[49]. The rate of exchange with a bicarbonate-containing 
solution should be more than the standard recommended 
dose of 25 ml/Kg/hour, modulated to correct acid–base 
status and electrolyte alterations. As to dialysis modalities, 
CRRT should be preferentially carried out with high per-
meability hemodialyzers, either by diffusion, convection or 
mixed techniques (Table 3).
Conclusions
Metformin is a well-known drug that has been used for more 
than 70 years, and that is still in the headlines due to its sur-
prising pleiotropic effects. Inserted by the WHO in the list of 
the safest and most effective drugs named “Essential Medi-
cines”, metformin is the most widely used oral antidiabetic 
drug in the world. Nowadays, metformin is a generic drug 
with a highly favorable cost-benefit ratio (monthly cost of 
therapy: from 2 to 6 euros), whose use is crucial for diabetes 
care in developing countries.
The clinical experience accumulated in these years has 
shown how lactic acidosis almost always develops because 
of a preventable drug accumulation. Patients taking the drug 
in the face of a concomitant complication which has led 
to reduced renal clearance of metformin (fever, diarrhea, 
vomiting, general malaise) must discontinue metformin. In 
the treatment of MALA patients, when standard support-
ive measures fail extracorporeal treatment should always be 
considered as early adjunctive therapy.
In conclusion, prevention is a key factor in reducing 
cases of MALA. By providing basic capillary information, 
patients should be made aware of the fact that even inappro-
priate discontinuation for a limited time does not affect their 
health, but it may prevent serious, potentially fatal adverse 
events.
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